

Real-world data demonstrates the consistent impact of the MiniMed™ 780G system on mealtime burden across Asia Pacific Region

New data from Australia, Japan, India, Singapore, Hong Kong, and South Korea demonstrates the MiniMed™ 780G is driving consistent clinical outcomes in diabetes management.

Medtronic plc, a global leader in medical technology, announced new clinical and real-world data to be presented at the inaugural [Medtronic Diabetes Asia Pacific Summit](#) in Singapore. New clinical evidence on the MiniMed™ 780G system will highlight the consistent outcomes and enhanced patient experience it's driving across the region despite unique dietary and lifestyle considerations of individuals living with diabetes in the Asia Pacific region. This data adds to a robust body of knowledge on the MiniMed™ 780G system's impact on patients with type 1 diabetes around the world.

- Mealtimes are cited as one of the biggest challenges for diabetes management and this is especially true for many Asian diets that often have "hidden" carbs that are difficult to count. As the only system with the Meal Detection™ technology algorithm* that automatically adjusts and corrects† glucose levels every 5 minutes‡, the MiniMed™ 780G system delivers up to 288 adjustments a day. The system helps cover undercounted carbs and an occasionally missed meal dose, thus helping achieve consistent clinical outcomes and Time in Range.
- Along with highlighting consistency in outcomes, the data will showcase the economic benefits of AID systems. As the long-term costs of diabetes for individuals, healthcare systems, and society continue to be at the forefront of discussions, data will be presented that highlights the health economic benefits of automated insulin delivery systems.
- An interactive and educational workshop of the CareLink™ system will demonstrate how the software transforms Time in Range data for HCPs. With a fresh look and feel, CareLink™ offers customized insights that can be tailored to a patient's needs and optimize therapy management.
- "Real-World Performance of the MiniMed™ 780G Safe Meal Bolus Feature" - short oral (#134) by Robert A. Vigersky, MD, Chief Medical Officer, Medtronic Diabetes on Monday, November 18, 15:20-15:25 SGT (2:20-2:25 CT)
- "Economic Benefits of Adopting the Subsidised Continuous Subcutaneous Insulin Infusion Pump for People with Type 1 Diabetes in Singapore" - short oral (#150) by Suresh Rama Chandran, MD, Senior Consultant of Endocrinology, Singapore General Hospital on Tuesday, November 19, 12:50-12:55 SGT (23:50-23:55 CT)
- "Real-World Evidence of Advanced Hybrid Closed-Loop System (MiniMed™ 780G) Compared to Hybrid Closed-Loop System (MiniMed™ 770G) in Korea: A Nationwide Retrospective Study" - long oral (#188) by Jun Sung Moon, Professor, Division of Endocrinology and Metabolism, Yeungnam University College of Medicine on Tuesday, November 19, 13:10-13:25 SGT (00:10-00:25 CT)
- "Use of Optimal Settings in the Medtronic 780G Enables Good Glycemic Control Despite Lower Carbohydrate Entry: Data from Singapore and Malaysia" - long oral (#233) by Daphne Gardner, BMBCh, Senior Consultant Endocrinologist, Singapore General Hospital on Tuesday, November 19, 13:25-13:40 SGT (00:25-00:40 CT)
- "Hyperglycemia from Real-World Dawn Phenomenon is Nearly Eliminated with the MiniMed™ 780G System (MM780G)" - long oral (#132) by Robert A. Vigersky, MD, Chief Medical Officer, Medtronic Diabetes on Tuesday, November 19, 13:55-14:10 SGT (00:55-1:10 CT)
- "MiniMed™ Advanced Hybrid Closed-Loop (AHCL) Use with Insulin Lispro-AABC in Adults with Type 1 Diabetes" - long oral (#133) by Andrew S. Rhinehart, MD, FACP, FACE, CDCES, Senior Medical Director, Medtronic Diabetes on Tuesday, November 19, 14:10-14:25 SGT (1:10-1:25 CT)**
- "The Outcomes of MiniMed™ 780G Advanced Hybrid Closed-Loop (AHCL) in Type 1 Diabetes (T1D): Japan Experience" - long oral (#34) by Nariko Kodani, MD, Department of Diabetes and Endocrinology, National Center for Global Health and Medicine in Japan, on Tuesday, November 19, 14:25-14:35 SGT (1:25-1:35 CT)
- "Improving Patient Outcomes for Users of MiniMed™ 780G System: Insights from the Analysis of Real-World Data of 1032 People Living with Diabetes in India" - long oral (#148) by Viswanathan Mohan, MD, PhD, DSc, FRCP, FNA, FACE, Chairperson of Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, on Tuesday, November 19, 14:25-14:40 SGT (1:25-1:40 CT)
- "Safety and Glycemic Outcomes of Adults with Type 2 Diabetes (T2D) in a MiniMed™ Advanced Hybrid Closed-Loop System Trial" - long oral (#125) by Andrew S. Rhinehart, MD, FACP, FACE, CDCES, Senior Medical Director, Medtronic Diabetes on Tuesday, November 19, 14:45-14:55 SGT (1:45-1:55 CT)***
- "MiniMed™ 780G System: Real-World Outcomes from 17,226 Users from Across the Asia-Pacific Region" - long oral (#212) by John J. Shin,

PhD, MBA, Senior Clinical Research Director, Medtronic Diabetes on Tuesday, November 19, 14:55-15:05 SGT (1:55-2:05 CT)

- "System Settings and User Factors Associated with Glucose Target Attainment from Real-World MiniMed™ 780G Advanced Hybrid Closed-Loop Users in Hong Kong" - long oral (#227) by Prof. Elaine Chow, PhD, Faculty of Medicine, The Chinese University of Hong Kong on Tuesday, November 19, 15:05-15:15 SGT (2:05-2:15 CT)
 - "The Majority of Australian MiniMed™ 780G Users Achieve International Consensus Guidelines of Glycemic Control" - long oral (#231) by Prof. Alicia Jenkins, MD, endocrinologist and clinician researcher, Baker Heart and Diabetes Institute on Tuesday, November 19, 15:15-15:25 SGT (2:15-2:25 CT)
 - "The Myth of MARD: Limitations of the Mean Absolute Relative Difference Metric"- long oral (#124) by Robert A. Vigersky, MD, Chief Medical Officer, Medtronic Diabetes on Wednesday, November 20, 08:50-09:00 SGT (19:50-20:00 CT)
 - "Assessing the Budget Impact of Adopting an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Singapore" - poster (#147) by Daphne Gardner, BMBCh, Senior Consultant Endocrinologist, Singapore General Hospital
-
- Medtronic Plenary Session: "Leveling the Playing Field in the Management of Type 1 Diabetes: From Algorithm to Advocacy" on Monday, November 18 15:40-16:40 (2:40-3:40 CT) (Sophia Hall), chaired by Muhammad Yazid Jalaludin, Professor and Pediatric Endocrinologist, Universiti Malaya.

Automated Insulin Delivery Workshop on Monday, November 18, 8:00-12:30 SGT (19:00-23:30 CST) featuring:

- Prof. Tadej Battelino, MD, PhD, Head of Endocrinology, University of Ljubljana
- Klemen Dovc, MD, Department of Paediatric and Adolescent Endocrinology, Diabetes and Metabolism, University Children's Hospital Ljubljana
- Viral Shah, MD, Associate Professor, Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado School of Medicine
- Ali Dianaty, SVP Product Innovation and Operations, Medtronic Diabetes
- Daphne Gardner, BMBCh, Senior Consultant Endocrinologist, Singapore General Hospital
- Nariko Kodani, MD, Department of Diabetes and Endocrinology, National Center for Global Health and Medicine, Japan
- Sarah Glastras, MBBS, PhD, Associate Professor of Endocrinology, University of Sydney
- Robert A. Vigersky, MD, Chief Medical Officer, Medtronic Diabetes

www.medtronicdiabetes.com

Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

**Taking a bolus 15 - 20 min before a meal helps to keep blood sugar levels under control after eating.*

† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.

§ Refers to SmartGuard™ feature. Individual results may vary.

***The MiniMed™ 780G system has not been approved for use with Lyumjev™ ultra-rapid insulin by FDA or other regulatory bodies.*

****The MiniMed™ 780G system has not been approved for use in type 2 diabetes by FDA or other regulatory bodies. The 780G system is only approved for use by FDA and other regulatory bodies in patients with type 1 diabetes.*

Ashley Patterson
Global Communications
+1 (818) 576-3025

Ryan Weispfenning
Investor Relations
+1 (763) 505-4626

https://stage.mediaroom.com/minimed_mr/2024-11-07-Real-world-data-demonstrates-the-consistent-impact-of-the-MiniMed-TM-780G-system-on-mealtime-burden-across-Asia-Pacific-Region